Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Romosozumab From Amgen Inc (AMGN) Shows Positive Results In Osteoporosis

Romosozumab (AKA romo) from Amgen Inc (NASDAQ:AMGN) and Belgium-based UCB, which is in its Phase III FRAME study is yet to achieve any regulatory approval from the FDA until some time next year. However, the study, which involved more than 7,000 women with osteoporosis, revealed that it is close to meeting both primary and secondary endpoints given that it has portrayed a 73%-75% reduction rate of vertebrae fractures. It is also showing a reduction of the incidence of clinical fractures, which commonly occur in postmenopausal women.

However, it missed out on one of the secondary endpoints, which is a 25% reduction rate compared to placebo in the risk of non-vertebral fractures. Executive vice president of Research and Development at Amgen Inc (NASDAQ:AMGN), Sean Harper, explains that a vertebral fracture, which is caused by osteoporosis, is life-threatening and that one in every two women over the age of 50 will experience an osteoporotic fracture.

amgen, logo, economy, symbol, deutschland, name, markenname, germany, emblem, berlin, icon, embleme, brand, german, company, marke

360b /

The FRAME Study

The 24-month study involved an analysis of results from 7,180 women who had a one year intake of monthly 210 mg subcutaneous injections of romosozumab or placebo. This intake would be followed by 12 months of open-label denosumab treatment for both arms. The results were positive from the group that received romosozumab compared to the placebo group.

The use of Romosozumab followed by denosumab had a 75% reduction in risk of vertebral fractures including the relative risk of new vertebral fracture unlike placebo followed by osteoporosis drug denosumab. However, chief medical officer and executive vice president of UCB, Iris Loew-Friedrich, is advocating for a deeper understanding of the results, which will help in sharpening the profile of romosozumab.

The drug is in a race with rival biotech Radius Health Inc (NASDAQ:RDUS), whose EU approval is also set by the end of the year. But it has a competitive edge given that its treatment is only once a month unlike that of Radius’ drug, which is injected daily. However, some analysts insist that of Radius may have a stronger effect.

Meanwhile, Amgen Inc (NASDAQ:AMGN)’s treatment has already hit its Phase III Bridge study primary endpoint of increasing bone mineral density of lumbar spine compared to placebo. The projected 2017 launch for romo has a consensus forecast of $650 million of revenue by 2020 even as UCB and Amgen plan to have its results discussed with global regulators as they both look forward to the 2016 filing.

Follow Amgen Inc (NASDAQ:AMGN)
Trade (NASDAQ:AMGN) Now!

Note: This article is written by Andy Parker and originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.